Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 63187-427

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 63187-427). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)

This text shows a chart indicating the probability of achieving systolic blood pressure less than 140 mm Hg after eight weeks of treatment with Valsartan and Hydrochlorothiazide, compared to a placebo group. The treatment group had a dose of 320 mg/25 mg of the two medications, while the placebo group did not receive active treatment. The baseline systolic blood pressure for all participants was between 145 and 180 mm Hg.*

FDA Label Image

63187-427-90 (Valhyctz Fig11)

This is a description of the medication Valsartan HCTZ 320mg/12.5mg. It comes in pink colored, oval-shaped, beveled edge, biconvex film-coated tablets. The tablets are available in two quantities, 30 and 90, and have a unique serial number, lot number 00000, and expiration date 00/00/00. Each tablet contains Valsartan USP 320mg and hydrochlorothiazide USP 12.5mg. The medicine is for prescription use only and must be stored at a temperature range of 20 degrees Celsius to 25 degrees Celsius. The medication is manufactured by Aurobindo Pharma Limited, Hyderabad, India, and is relabeled by Proficient Rx LP.*

FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)

The figure shows the probability of achieving diastolic blood pressure below 90 mmHg at Week 8, with baseline DBP ranging from 95 to 105 mmHg. There is no other available information in the given text.*

FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)

The given text describes a figure (Figure 3) that shows the probability of achieving systolic blood pressure less than 130 mmHg at week 8. The text also mentions the doses of Valsartan and Hydrochlorothiazide used for achieving the desired blood pressure level. The figure plots the baseline SBP starting from 140 until 180 on the x-axis and the probability of achieving SBP <130 mmHg on the y-axis.*

FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure &lt;80 Mmhg At Week 8 (Valhyctz Fig4)

This is the result of a clinical study evaluating the probability of achieving a DBP (diastolic blood pressure) of <80 mmHg at week 8 while using Valsartan and Hydrochlorothiazide with a dosage of 320 mg/25mg. The chart shows that at baseline (starting point), the percentage was at 100% for achieving a DBP of <80 mmHg, and by week 8, the probability decreased to 95%. The study includes a placebo-controlled group for comparison.*

FDA Label Image

Valsartan Chemical Structure (Valhyctz Str1)

FDA Label Image

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.